292 related articles for article (PubMed ID: 27999208)
21. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
[TBL] [Abstract][Full Text] [Related]
22. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.
Sturgeon SR; Balasubramanian R; Schairer C; Muss HB; Ziegler RG; Arcaro KF
Epigenetics; 2012 Nov; 7(11):1258-67. PubMed ID: 22986510
[TBL] [Abstract][Full Text] [Related]
23. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor DNA
Sun X; Li H; Sun M; Yuan Y; Sun L
Future Oncol; 2019 Oct; 15(30):3513-3525. PubMed ID: 31578881
[No Abstract] [Full Text] [Related]
25. Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Zhang L; Long X
Sci Rep; 2015 Dec; 5():17869. PubMed ID: 26643130
[TBL] [Abstract][Full Text] [Related]
26. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
27. E74-like Factor 5 Promoter Methylation in Circulating Tumor DNA as a Potential Prognostic Marker in Breast Cancer Patients.
Salimi M; Rastegarpouyani S
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4035-4041. PubMed ID: 38156835
[TBL] [Abstract][Full Text] [Related]
28. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
Huang YT; Li FF; Ke C; Li Z; Li ZT; Zou XF; Zheng XX; Chen YP; Zhang H
J Transl Med; 2013 Oct; 11():245. PubMed ID: 24090193
[TBL] [Abstract][Full Text] [Related]
29. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
Jing F; Zhang J; Tao J; Zhou Y; Jun L; Tang X; Wang Y; Hai H
Onkologie; 2007 Feb; 30(1-2):14-9. PubMed ID: 17264521
[TBL] [Abstract][Full Text] [Related]
30. Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
Li SY; Li R; Chen YL; Xiong LK; Wang HL; Rong L; Luo RC
BMC Genet; 2014 Jun; 15():67. PubMed ID: 24919593
[TBL] [Abstract][Full Text] [Related]
31. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients.
Ng EK; Leung CP; Shin VY; Wong CL; Ma ES; Jin HC; Chu KM; Kwong A
PLoS One; 2011; 6(7):e22233. PubMed ID: 21789241
[TBL] [Abstract][Full Text] [Related]
32. APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta-analysis.
Qian X; Ruan L
Thorac Cancer; 2018 Feb; 9(2):284-290. PubMed ID: 29297603
[TBL] [Abstract][Full Text] [Related]
33. Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases.
Gao X; Li LY; Rassler J; Pang J; Chen MK; Liu WP; Chen Z; Ren SC; Zhou FJ; Xie KJ; Zhou X; Qian HJ; Bai XZ; Liu JM; Yang JG; He D; Shao CK; Su ZL; Wang J; Qiu JG; Ling L
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28122909
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study.
Brooks JD; Cairns P; Shore RE; Klein CB; Wirgin I; Afanasyeva Y; Zeleniuch-Jacquotte A
Cancer Epidemiol; 2010 Dec; 34(6):717-23. PubMed ID: 20627767
[TBL] [Abstract][Full Text] [Related]
35. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E
Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
37. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
38. The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer.
Xue WJ; Feng Y; Wang F; Li P; Liu YF; Guo YB; Wang ZW; Mao QS
Tumour Biol; 2016 Aug; 37(8):11249-57. PubMed ID: 26945573
[TBL] [Abstract][Full Text] [Related]
39. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
40. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
